Tumor growth in pancreatic cancer xenografts

Tumor growth in pancreatic cancer xenografts is a physiological process and experimental readout used to assess the in vivo efficacy of anti-cancer therapies (National Cancer Institute, 2023). This process involves the proliferation of human-derived pancreatic cancer cells (Cell-line Derived Xenografts, CDX) or patient-derived tumor fragments (Patient-Derived Xenografts, PDX) within an immunocompromised host, such as a nude or SCID mouse (Nature Reviews Cancer, 2019). It is not a discrete molecular target but a phenotypic manifestation of underlying oncogenic drivers like KRAS mutations, TP53 alterations, and SMAD4 deletions (PubMed, PMID: 31213456). Drugs such as gemcitabine or nab-paclitaxel are frequently tested against this process to measure their ability to induce tumor regression or growth inhibition (Clinical Cancer Research, 2021). While these models provide critical data on drug pharmacodynamics and dose-response relationships, they often fail to fully replicate the dense desmoplastic stroma and complex immune landscape characteristic of human pancreatic ductal adenocarcinoma (Journal of Hematology & Oncology, 2020).

Other names

Pancreatic cancer xenograft growthPDX growthCDX growthPancreatic tumor progression in vivoPancreatic cancer cell line xenograft growth

Not applicable. This is a physiological process and experimental endpoint used to measure drug efficacy, rather than a specific molecular target that a drug binds to.